Fig. 1From: Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in GermanyReasons for initiation of treatment with a monoclonal antibody – physicians’ perspective. N = 45 (number of physicians); QoL=quality of life; MMD=monthly migraine days; Seven distinct reasons for the initiation of treatment with a monoclonal antibody were evaluated by the treating physician according to the level of importanceBack to article page